SEC Form 4 · accession 0001213900-15-000634
Icagen, Inc. · ICGN
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Richard Anthony Cunningham
Officer — President and CEO
Period of report
Jan 7, 2015
Accepted (ET)
Feb 2, 2015 · 12:53 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001518520
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock optionsF1,F2 | $1.75 | Jan 7, 2015 | A | 500,000 | A | Nov 24, 2015 | Jan 6, 2025 | Common Stock | 500,000 | 500,000 | D |
Explanation of responses
- F1Pursuant to the terms of Mr. Cunningham's employment agreement (the "Employment Agreement") with XRpro Sciences Inc. (f/k/a Caldera Pharmaceuticals, Inc.) (the "Company"), Mr. Cunningham was awarded options exercisable for 500,000 shares of the Company's common stock on the closing date of the Company's first financing subsequent to Mr. Cunningham becoming the Company's President and Chief Executive Officer.
- F2The options vest as follows: (i) 100,000 options vest on November 24, 2015; (ii) 300,000 options vest monthly on a pro rata basis commencing on the last day of months thirteen (13) through forty eight (48) of the term of the Employment Agreement, which ends on November 24, 2018, unless terminated earlier; and (iii) 100,000 options vest on November 24, 2018.